Most Popular
-
1
Actor Jung Woo-sung admits to being father of model Moon Ga-bi’s child
-
2
Wealthy parents ditch Korean passports to get kids into international school
-
3
Man convicted after binge eating to avoid military service
-
4
First snow to fall in Seoul on Wednesday
-
5
Final push to forge UN treaty on plastic pollution set to begin in Busan
-
6
Korea to hold own memorial for forced labor victims, boycotting Japan’s
-
7
Nvidia CEO signals Samsung’s imminent shipment of AI chips
-
8
Job creation lowest on record among under-30s
-
9
NK troops disguised as 'indigenous' people in Far East for combat against Ukraine: report
-
10
Opposition leader awaits perjury trial ruling
Samsung Biologics said Monday it has signed a contract to develop PharmAbcine’s anti-cancer and angiogenesis material PMC-402.
The South Korean firm will provide all-step CDO support from cell line development to clinical sample manufacturing and investigational new drug application, as well as produce preclinical and global clinical trial materials.
PMC-402, according to PharmAbcine, helps normalize newly formed abnormal blood vessels that feed the growth of tumors, or the condition called angiogenesis.
Yoo Jin-san, president and CEO of PharmAbcine, said that the anti-cancer qualities of PMC-402 was proven in independent research and in combination with immuno-oncology drugs.
The drug has potential to have therapeutic effects for ophthalmological malconditions such as diabetic retinopathy and age-related macular degeneration.
PharmAbcine plans to enter global phase 1 clinical trials from 2021.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
The South Korean firm will provide all-step CDO support from cell line development to clinical sample manufacturing and investigational new drug application, as well as produce preclinical and global clinical trial materials.
PMC-402, according to PharmAbcine, helps normalize newly formed abnormal blood vessels that feed the growth of tumors, or the condition called angiogenesis.
Yoo Jin-san, president and CEO of PharmAbcine, said that the anti-cancer qualities of PMC-402 was proven in independent research and in combination with immuno-oncology drugs.
The drug has potential to have therapeutic effects for ophthalmological malconditions such as diabetic retinopathy and age-related macular degeneration.
PharmAbcine plans to enter global phase 1 clinical trials from 2021.
By Lim Jeong-yeo (kaylalim@heraldcorp.com)
